Clinical trials
Postoperative Adjuvant Treatment clinical trials
Below are recruiting postoperative adjuvant treatment clinical trials, each written for real people, not researchers. We’re tracking 55 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04495088RecruitingPhase 3
Before vs after chemotherapy for locally advanced rectal cancer
This Phase 3 study compares giving chemotherapy before rectal surgery versus giving it after surgery, using a tailored plan based on your risk. The goal is to see which timing helps more people with locally advanced rectal cancer stay cancer-free and live longer.
MannheimAges 18 years+ - NCT07684508Recruiting
Shorter radiation therapy after surgery for cervical cancer
This trial tests a shorter course of radiation therapy (fewer sessions) after hysterectomy for cervical cancer. It aims to see if it's safe and effective for patients who meet certain criteria based on their tumor type and recovery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06501482RecruitingPhase 3
FOLFIRI after liver surgery for colorectal cancer
This trial tests whether adding FOLFIRI chemotherapy after surgery for liver metastases from colorectal cancer can reduce the risk of the cancer coming back. It's for people whose liver tumors responded well to the same chemotherapy before surgery.
Paris, Île-de-France RegionAges 18 years+ - NCT07067385RecruitingPhase 1
Personalized mRNA vaccine for advanced GI cancers
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
Shanghai, SHAges 18 years+ - NCT07670026RecruitingPhase 2
Stronger treatment after surgery for high-risk glioblastoma
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
Hangzhou, ZhejiangAges 18 years+ - NCT06476119Recruiting
Optimizing treatment for low stage triple-negative breast cancer with high immune cells
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
Sittard-Geleen, LimburgAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70
Hear when a new Postoperative Adjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for postoperative adjuvant treatment?
- Yes. Clin2 currently lists 55 recruiting postoperative adjuvant treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a postoperative adjuvant treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a postoperative adjuvant treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.